Literature DB >> 7745120

Soluble forms of the adhesion molecule E-cadherin in urine.

R E Banks1, W H Porter, P Whelan, P H Smith, P J Selby.   

Abstract

The adhesion molecule E-cadherin is essential for maintaining epithelial intercellular adhesion. Loss or reduced expression of E-cadherin has been related to invasive behaviour in a wide range of carcinomas. Using immunoblotting techniques, the existence of multiple soluble forms of E-cadherin was demonstrated in urine from healthy volunteers and patients with benign urinary tract disorders or bladder cancer. The existence of soluble forms of E-cadherin in the urine may reflect shedding from the urinary tract epithelium as part of the normal turnover of this molecule. The possibility that enhanced shedding may contribute to the loss of E-cadherin expression/function in malignancy is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7745120      PMCID: PMC502407          DOI: 10.1136/jcp.48.2.179

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Single amino acid substitutions in one Ca2+ binding site of uvomorulin abolish the adhesive function.

Authors:  M Ozawa; J Engel; R Kemler
Journal:  Cell       Date:  1990-11-30       Impact factor: 41.582

Review 2.  Circulating adhesion molecules in disease.

Authors:  A J Gearing; W Newman
Journal:  Immunol Today       Date:  1993-10

3.  Soluble 80-kd fragment of cell-CAM 120/80 disrupts cell-cell adhesion.

Authors:  M J Wheelock; C A Buck; K B Bechtol; C H Damsky
Journal:  J Cell Biochem       Date:  1987-07       Impact factor: 4.429

4.  Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas.

Authors:  Y Shimoyama; S Hirohashi; S Hirano; M Noguchi; Y Shimosato; M Takeichi; O Abe
Journal:  Cancer Res       Date:  1989-04-15       Impact factor: 12.701

5.  Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors.

Authors:  P P Bringuier; R Umbas; H E Schaafsma; H F Karthaus; F M Debruyne; J A Schalken
Journal:  Cancer Res       Date:  1993-07-15       Impact factor: 12.701

6.  Cadherin dysfunction in a human cancer cell line: possible involvement of loss of alpha-catenin expression in reduced cell-cell adhesiveness.

Authors:  Y Shimoyama; A Nagafuchi; S Fujita; M Gotoh; M Takeichi; S Tsukita; S Hirohashi
Journal:  Cancer Res       Date:  1992-10-15       Impact factor: 12.701

7.  Identification and purification of a cell surface glycoprotein mediating intercellular adhesion in embryonic and adult tissue.

Authors:  C H Damsky; J Richa; D Solter; K Knudsen; C A Buck
Journal:  Cell       Date:  1983-09       Impact factor: 41.582

Review 8.  Cadherins in cancer: implications for invasion and metastasis.

Authors:  M Takeichi
Journal:  Curr Opin Cell Biol       Date:  1993-10       Impact factor: 8.382

9.  Altered expression of E-cadherin in gastric cancer tissues and carcinomatous fluid.

Authors:  K Matsuura; J Kawanishi; S Fujii; M Imamura; S Hirano; M Takeichi; Y Niitsu
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

10.  Soluble E-cadherin fragments increased in circulation of cancer patients.

Authors:  M Katayama; S Hirai; K Kamihagi; K Nakagawa; M Yasumoto; I Kato
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

  10 in total
  16 in total

1.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine.

Authors:  A Vlahou; P F Schellhammer; S Mendrinos; K Patel; F I Kondylis; L Gong; S Nasim; G L Wright
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  E-cadherin gene 3'-UTR C/T polymorphism in Turkish patients with nephrolithiasis.

Authors:  Akin Yilmaz; Sevda Menevse; Metin Onaran; Ilker Sen; Mehmet Ali Ergun; Ahmet Camtosun; Bora Kupeli; Ibrahim Bozkirli
Journal:  Mol Biol Rep       Date:  2010-12-14       Impact factor: 2.316

Review 3.  Regulation of E-cadherin: does hypoxia initiate the metastatic cascade?

Authors:  I R Beavon
Journal:  Mol Pathol       Date:  1999-08

4.  Stage-specific quantitative changes in renal and urinary proteome during the progression and development of streptozotocin-induced diabetic nephropathy in rats.

Authors:  Vikram Sharma; Kulbhushan Tikoo
Journal:  Mol Cell Biochem       Date:  2013-11-27       Impact factor: 3.396

Review 5.  Soluble cadherins as cancer biomarkers.

Authors:  Olivier De Wever; Lara Derycke; An Hendrix; Gert De Meerleer; François Godeau; Herman Depypere; Marc Bracke
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

6.  [Use of silicon chip technology to detect protein-based tumor markers in bladder cancer].

Authors:  T Jäger; T Szarvas; F vom Dorp; C Börgermann; M Schenck; K W Schmid; H Rübben
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

7.  Matrix Metalloproteinases as Mediators of Primary and Secondary Cataracts.

Authors:  Judith A West-Mays; Giuseppe Pino
Journal:  Expert Rev Ophthalmol       Date:  2007

8.  Soluble serum E-cadherin as a marker of tumour progression in colorectal cancer patients.

Authors:  C Wilmanns; J Grossmann; S Steinhauer; G Manthey; B Weinhold; A Schmitt-Gräff; B U von Specht
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

9.  Circulating soluble adhesion molecules E-cadherin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in patients with gastric cancer.

Authors:  G Velikova; R E Banks; A Gearing; I Hemingway; M A Forbes; S R Preston; M Jones; J Wyatt; K Miller; U Ward; J Al-Maskatti; S M Singh; N S Ambrose; J N Primrose; P J Selby
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence.

Authors:  T R Griffiths; I Brotherick; R I Bishop; M D White; D M McKenna; C H Horne; B K Shenton; D E Neal; J K Mellon
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.